Protara Therapeutics Releases STARBORN-1 Trial Data

Protara Therapeutics Releases STARBORN-1 Trial Data
Protara Therapeutics, Inc. announced interim safety and durability findings from its STARBORN-1 clinical trial evaluating TARA-002 for treating lymphatic malformations. The biotech company presented comprehensive data examining both the short-term safety profile and long-term durability of the investigational therapy in patient populations suffering from this rare vascular disorder. Lymphatic malformations represent a significant clinical challenge, affecting patients with abnormal lymphatic vessel development that can cause complications including pain, infection, and functional impairment. The STARBORN-1 trial represents an important step in developing therapeutic options for this underserved patient population with limited existing treatment alternatives.